Received Apr 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | f95ys | — |
patient had first dose one year ago/late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 69-year-old male patient who received Herpes zoster (Shingrix) (batch number f95ys, expiry date 31-MAR-2027) for prophylaxis. Previously administered products included Shingrix (Patient had first dose one year ago). On 04-APR-2025, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient had first dose one year ago/late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 04-APR-2025 Patient had 1 dose Shingrix 1 year ago and second dose on the day of reporting. Also asked how many doses does patient need of Shingrix if 2 dose given 1 year after 1st. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccinations schedule.